CN116203241A - Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 - Google Patents
Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 Download PDFInfo
- Publication number
- CN116203241A CN116203241A CN202310271576.0A CN202310271576A CN116203241A CN 116203241 A CN116203241 A CN 116203241A CN 202310271576 A CN202310271576 A CN 202310271576A CN 116203241 A CN116203241 A CN 116203241A
- Authority
- CN
- China
- Prior art keywords
- trim26
- colon cancer
- protein
- expression
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 title claims abstract description 53
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 title claims abstract description 53
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 49
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 44
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 238000002331 protein detection Methods 0.000 title abstract description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 37
- 238000004393 prognosis Methods 0.000 claims abstract description 17
- 238000003745 diagnosis Methods 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 238000010837 poor prognosis Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 23
- 238000002306 biochemical method Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims description 2
- 238000004817 gas chromatography Methods 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 238000004879 turbidimetry Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000006399 behavior Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000042631 TRIM/RBCC family Human genes 0.000 description 1
- 108091053398 TRIM/RBCC family Proteins 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于医学诊断技术领域，具体涉及TRIM26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途。所述TRIM26蛋白的NCBI登录号为NP_001229712，所述诊断和预后的受试者为人，所述检测的样本为受试者的组织。本发明所述的TRIM26蛋白高表达与结肠癌的发生及恶性生长行为相关，相较于健康对照，TRIM26蛋白高表达指示受试者患有结肠癌或有患结肠癌的风险；结肠癌患者组织样本中TRIM26蛋白表达升高，判定为不良预后；结肠癌患者组织样本中TRIM26蛋白表达降低，判定为良好预后。结果提示TRIM26蛋白是一个潜在的结肠癌治疗靶点。
Description
技术领域
本发明属于医学诊断技术领域，具体涉及TRIM26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途。
背景技术
结直肠癌是恶性程度非常高的肿瘤之一，其发病率和死亡率有明显增高的趋势。全球每年约有120万的新发病例，约有50万人死于结直肠癌，已成为第三大类癌症死因。我国每年有近50万人患病，死亡率为44％。由于肿瘤具有高度侵袭性及转移性导致治疗效果降低及患者预后不良，因而早期诊断及治疗有助于改善患者预后。三结构域(tripartitemotif，TRIM)家族蛋白可调控肿瘤细胞的增殖、转移、凋亡和自噬等多种生物学行为，介导泛素化、染色体异位和转录、p53信号通路和NF-κB信号通路等分子调控机制。TRIM26作为TRIM超家族成员之一，已发现其在部分肿瘤中发挥重要作用。如TRIM26在肝癌组织中表达下调，与肝癌细胞的增值、迁移和侵袭能力呈负相关，并促进细胞凋亡，发挥抑癌作用；TRIM26限制了肺癌的生长,过表达TRIM26可通过下调BCL-2抑制细胞生长并诱导细胞凋亡；沉默TRIM26表达可抑制乳腺癌MCF-7细胞增殖、侵袭与迁移能力，并诱导细胞凋亡，其机制可能与抑制PI3K/AKT/mTOR信号通路有关；TRIM26在胶质瘤组织中呈高表达，过表达TRIM26可促进胶质瘤细胞U87及U251的增殖。但TRIM26在结肠癌中的表达及机制尚不清楚。
发明内容
本发明的目的探讨TRIM26在结肠癌癌变过程中的表达差异及其表达与临床指标的相关性；分析TRIM26表达差异对患者生存率的影响，并分析结肠癌预后的独立相关因素；分析TRIM26与年龄、MMR主导蛋白、PDL1间质2的相关性，以期为提高结肠癌患者的预后奠定基础。
为实现上述目的，本发明提供如下技术方案：
TRIM26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途，所述TRIM26蛋白的NCBI登录号为NP_001229712。
进一步的，上述用途中，所述诊断和预后的受试者为人。
上述用途中，作为一种优选的实施方案，所述检测的样本为受试者的组织。
进一步的，相较于健康对照，TRIM26蛋白高表达指示受试者患有结肠癌或有患结肠癌的风险。
进一步的，结肠癌患者组织样本中TRIM26蛋白表达升高，判定为不良预后；结肠癌患者组织样本中TRIM26蛋白表达降低，判定为良好预后。
上述用途中，所述检测试剂为定量检测所述TRIM26蛋白表达量的试剂。
进一步的，上述用途中，所述检测的方法为放射方法、免疫方法、荧光方法、流式荧光法、胶乳比浊法、生化法、酶法、杂交法、气质联用法、液质联用法、层析法、化学发光方法、磁电法或光电转换方法。
与现有技术相比，本发明具有如下有益效果：
本发明研究结果表明：TRIM26蛋白在结肠癌组织中的表达明显高于癌旁组织(P<0.001)；TRIM26表达与病理分级、N分期、TNM分期、PDL-1密切相关(P＜0.05)；生存分析显示，癌组织TRIM26表达与结肠癌的不良预后显著相关(P＝0.014)。该结果提示检测TRIM26对于结肠癌的诊断、判断预后有重要意义，TRIM26蛋白是一个潜在的结肠癌治疗靶点。
附图说明
图1为TRIM26蛋白的免疫组化实验结果，其中，A为TRIM26蛋白在结肠癌组织中的表达情况；B为TRIM26蛋白在癌旁正常组织中的表达情况。
图2为TRIM26在结肠癌及癌旁组织中的表达比较。***Statisticallysignificant(p<0.001)。
图3为TRIM26表达量与结肠癌患者预后的相关性。
具体实施方式
下面结合附图和具体实施例对本发明进行详细说明，但不应理解为本发明的限制。如未特殊说明，下述实施例中所用的技术手段为本领域技术人员所熟知的常规手段，下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1
1材料与方法
1.1组织样本来源
104例结肠癌患者样本来源于上海芯超生物科技有限公司的组织样本库，手术时间为2006年7月至2007年5月，最终随访时间均为2015年7月。所有病例均病理确诊为结肠癌，并且未接受任何术前治疗。男性58例，女性45例，1例未知。年龄24-90岁，中位年龄57岁。每例均包含癌组织和相匹配的距离癌1.5cm的癌旁组织。104例结直肠癌患者的临床病理资料见表1。
表1 104例结直肠癌患者的临床病理资料
1.2组织芯片制作
由上海芯超生物科技有限公司完成组织芯片的制作。所有供体组织蜡块行常规病理切片后进行HE染色，由病理专家作二次诊断，并在HE切片上标记典型病理部位。使用组织芯片制作仪(BeecherInstruments.Inc)在受体蜡块(空白蜡块)上打孔(直径1.5mm)，然后根据HE片上的标记范围在供体组织蜡块相应位置获取目标组织芯放入受体蜡块阵列孔中，重复上述步骤，最终制作完成1个结肠癌组织和癌旁组织匹配的180点阵列块(HCol-Ade180Sur-06)。采用切片机(Leica，德国)以4-5um厚度连续切片，切片裱附在经过防脱片处理的进口载玻片上制成组织芯片。
1.3免疫组织化学实验
EnVision二步法进行免疫组织化学实验。在光学显微镜下随机观察3个高倍镜视野，记不少于3×100个细胞中的阳性细胞数，计算阳性细胞数占整个细胞数的染色阳性率。以“染色强度评分”和“染色阳性率评分”的乘积为总评分进行分组，＜12分为抗体低表达组，≥12分为抗体高表达组。
1.4统计学分析
TRIM26蛋白在结肠癌和癌旁组织中的表达情况采用卡方检验分析。TRIM26表达与结肠癌患者临床指标相关性采用卡方检验分析，P值＜0.05具有统计学意义。TRIM26蛋白与结肠癌预后的相关性分析：采用Kaplan-Meier生存分析法和log-rank统计检验进行生存期单因素分析；将单因素分析中有统计学意义的变量纳入COX多因素生存回归分析。P<0.05有统计学意义。TRIM26与年龄、MMR主导蛋白、PDL1间质2的相关性采用Spearman's相关性分析。
2实验结果
2.1TRIM26蛋白在结肠癌和癌旁组织中的表达分析
免疫组化实验结果显示：TRIM26蛋白在结肠癌和癌旁组织的细胞浆表达(图1)。卡方检验分析显示：TRIM26在结肠癌中表达显著高于癌旁组织(p<0.001)，分析结果见图2。
2.2TRIM26表达与结肠癌患者临床指标相关性
卡方检验分析显示：TRIM26表达与病理分级、N分期、TNM分期、PDL-1密切相关(p＜0.05)。此外，TRIM26表达与年龄、性别、T分期、MLH1、MSH6、MSH2、PMS2之间无明显统计学关系(P＞0.05)，见表2。
表2TRIM26表达与结肠癌患者临床指标相关性
2.3TRIM蛋白表达与结肠癌预后的相关性分析
结肠癌病人的随访情况如下：手术时间为2006年7月至2007年5月，最终随访时间为2015年7月。随访期间，有63例病人死于结肠癌，中位随访时间28个月(1到87个月)；有41例病人仍存活，中位随访时间101个月(98到108个月)。采用Kaplan-Meier生存分析法和log-rank统计检验进行生存期单因素分析显示：癌组织TRIM26表达低的结肠癌病人拥有更长的总生存期(p＝0.014)，其5年生存率显著高于TRIM26表达高的结肠癌病人(图3)。
尽管已描述了本发明的优选实施例，但本领域内的技术人员一旦得知了基本创造性概念，则可对这些实施例作出另外的变更和修改。所以，所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然，本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样，倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内，则本发明也意图包含这些改动和变型在内。
Claims (7)
1.TRIM26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途，其特征在于，所述TRIM26蛋白的NCBI登录号为NP_001229712。
2.根据权利要求1所述的用途，其特征在于，所述诊断和预后的受试者为人。
3.根据权利要求2所述的用途，其特征在于，所述检测的样本为受试者的组织。
4.根据权利要求3所述的用途，其特征在于，相较于健康对照，TRIM26蛋白高表达指示受试者患有结肠癌或有患结肠癌的风险。
5.根据权利要求3所述的用途，其特征在于，结肠癌患者组织样本中TRIM26蛋白表达升高，判定为不良预后；结肠癌患者组织样本中TRIM26蛋白表达降低，判定为良好预后。
6.根据权利要求1所述的用途，其特征在于，所述检测试剂为定量检测所述TRIM26蛋白表达量的试剂。
7.根据权利要求6所述的用途，其特征在于，所述检测的方法为放射方法、免疫方法、荧光方法、流式荧光法、胶乳比浊法、生化法、酶法、杂交法、气质联用法、液质联用法、层析法、化学发光方法、磁电法或光电转换方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310271576.0A CN116203241B (zh) | 2023-03-20 | 2023-03-20 | Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310271576.0A CN116203241B (zh) | 2023-03-20 | 2023-03-20 | Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116203241A true CN116203241A (zh) | 2023-06-02 |
| CN116203241B CN116203241B (zh) | 2023-08-22 |
Family
ID=86511248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310271576.0A Active CN116203241B (zh) | 2023-03-20 | 2023-03-20 | Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116203241B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200278350A1 (en) * | 2019-02-28 | 2020-09-03 | Case Western Reserve University | Compositions and methods for determiinng cancer prognosis |
| CN113355422A (zh) * | 2021-03-02 | 2021-09-07 | 北京大学第一医院 | 一种用于人肿瘤分级的基因组合及其用途 |
-
2023
- 2023-03-20 CN CN202310271576.0A patent/CN116203241B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200278350A1 (en) * | 2019-02-28 | 2020-09-03 | Case Western Reserve University | Compositions and methods for determiinng cancer prognosis |
| CN113355422A (zh) * | 2021-03-02 | 2021-09-07 | 北京大学第一医院 | 一种用于人肿瘤分级的基因组合及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116203241B (zh) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petit et al. | Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy | |
| JP5971769B2 (ja) | アントラサイクリン療法を用いて乳癌を処置する方法 | |
| CN101027412B (zh) | 用于膀胱癌检测的尿标记物 | |
| JP6049739B2 (ja) | 前立腺癌の分類のためのマーカー遺伝子 | |
| MX2010014280A (es) | Distintivos y determinantes asociados con metástasis y método para utilizarlos. | |
| EP1735463A2 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer | |
| WO2008058018A2 (en) | Predicting cancer outcome | |
| CN108169490B (zh) | 一组用于评估胶质母细胞瘤预后的联合蛋白及其应用 | |
| Asioli et al. | Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer | |
| CN105102636A (zh) | 用于检测和测定前列腺癌预后的组合物和方法 | |
| Chan et al. | A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease | |
| CN104711341B (zh) | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 | |
| Scott et al. | A multi-scale integrated analysis identifies KRT8 as a pan-cancer early biomarker | |
| CN115612742B (zh) | 一种预测中晚期直肠癌新辅助治疗疗效的分子标志物模型及其应用 | |
| Malik et al. | Evaluating morphological features for predicting microsatellite instability status in colorectal cancer | |
| EP2680003A1 (en) | Serum biomarker for diagnosing colorectal cancer | |
| CN116203241B (zh) | Trim26蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 | |
| CN116298292B (zh) | Gng2蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途 | |
| CN114778844A (zh) | Pld1作为评估肿瘤患者对于化疗药物敏感性的分子标志物的用途 | |
| EP1934367A4 (en) | MOLECULAR METHOD FOR THE DIAGNOSIS OF PROSTATE CANCER | |
| US11448650B2 (en) | Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers | |
| CN112904006A (zh) | 一种乳腺癌预后预测分子标志物及其应用 | |
| JP5574522B2 (ja) | 癌マーカー及び癌細胞の検査方法 | |
| WO2013132001A1 (en) | Prognostic biomarkers for survival after treatment of a cancer disease with radiotherapy and/or chemotherapy | |
| US20230176061A1 (en) | Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |